On Monday, Gilead acquired KITE for $180 per share. Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. Over the past 30 years, Gilead has made significant advances that have improved the lives of people living with HIV … Kite Pharma Acquires Dutch Biotech Firm to Establish Amsterdam EHQ California biopharma company to strengthen cancer gene therapy platform through acquisition T-Cell Factory B.V. (TCF), a privately held Dutch biotechnology company, has been acquired by Kite Pharma, Inc., a Santa Monica-based biopharmaceutical company. The combined strength of Kite and Gilead allows us to remain innovative, agile, and ambitious in our mission to keep improving the lives of people with all types of cancer. The company is engaged in developing engineered cell therapies that express either a chimeric antigen receptor (CAR) or a T … Kite has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. But what Gilead saw this year gave Milligan the confidence to buy Kite Pharma, one of CAR-T's leaders, in a $11.9 billion deal that drew instant comparisons to … Kite is a leader in the emerging field of cell therapy, in which a person’s immune cells are activated to fight cancer. The following table lists the largest mergers and acquisitions in the pharmaceutical and biotechnology industry (those over $10 billion). "From the release of our pivotal data for axi-cel, to our potential approval by the FDA, this is a year of milestones. Under the terms of the merger agreement, a wholly-owned subsidiary of Gilead will promptly commence a tender offer to acquire all of the outstanding shares of Kite's common stock at a price of $180.00 per share in cash. For more information on Gilead Sciences, please visit the company's website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. Kite has additional candidates in clinical trials in both hematologic cancers and solid tumors, including KITE-585, a CAR T therapy candidate that targets BCMA expressed in multiple myeloma. For the latest updates on our ongoing response to COVID-19, please click here. "The acquisition of Kite establishes Gilead as a leader in cellular therapy and provides a foundation from which to drive continued innovation for people with advanced cancers," said John F. Milligan, PhD, Gilead's President and Chief Executive Officer. 3 Reasons to Applaud Gilead Sciences' Acquisition of Kite Pharma There's a lot to like with Gilead's buyout of cell therapy leader Kite Pharma. Alternatively, please call 1-877-359-9508 or 1-224-357-2393 (international) and dial the conference ID 77187238 to access the call. ", Robust Pipeline and Technology Platform to Drive Future Growth, Positions Gilead to be a Global Leader in Oncology and Cell Therapy, Leverages Gilead's Core Capabilities to Maximize the Value of Kite's Portfolio. Kite Pharma General Information Description. Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term, durable response and eliminating the burden of chronic care. Added David Chang, M.D., Ph.D., Kite Pharma's evp, research and development and CMO: “In addition to expanding our capabilities in TCR, this acquisition is … Stay logged in to skip the surveys. Kite Pharma has acquired 2 companies of its own, including 1 in the last 5 years.. Kite Pharma’s largest acquisition to date was in 2017, when it acquired Cell Design Labs for $567M.Kite Pharma has acquired in 1 US state, and 2 countries. On March 31, 2017, Kite submitted a Biologics License Application to the FDA for its lead product candidate, axi-cel, as a treatment for patients with relapsed or refractory aggressive non-Hodgkin lymphoma who are ineligible for autologous stem cell transplant. Kite Pharma General Information Description. The Tender Offer Statement and the Solicitation/Recommendation Statement will be made available for free at the Commission's web site at www.sec.gov. It is expected to be the first to market as a treatment for refractory aggressive non-Hodgkin lymphoma, which includes diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL). "The field of cell therapy has advanced very quickly, to the point where the science and technology have opened a clear path toward a potential cure for patients. At the time the offer is commenced, Gilead will file a Tender Offer Statement on Schedule TO with the U.S. Securities and Exchange Commission, and Kite will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. Source: Streetwise Reports Kite Pharma has acquired in 1 US state, and 2 countries. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Some content on this site is not intended for people outside the United States. The company is engaged in developing engineered cell therapies that express either a chimeric antigen receptor (CAR) or a T cell receptor (TCR), depending on the type of cancer. These potential With the addition of Kite’s CAR T and TCR cellular therapy platforms, we believe that together we can bring that same kind of innovation to cancer. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Gilead isn't buying Kite Pharma just for the drugs it's developing. Register for more free articles. Over the past 30 years, Gilead has made significant advances that have improved the lives of people living with HIV and, over the past four years, has introduced four medicines that offer a cure for chronic hepatitis C virus. This announcement is neither an offer to purchase nor a solicitation of an offer to sell shares of Kite. The FDA has set a target action date of November 29, 2017 under the Prescription Drug User Fee Act (PDUFA). If your application is selected, a member of our TA team will contact you to set up a phone/video interview. Kite Pharma is a division of Gilead Sciences based in California. It started with the late 2017 acquisition of Kite Pharma for $11.9 billion. The KITE acquisition will spur a number of acquisitions … This submission comes after positive results from Kite's ZUMA-1 pivotal trial with axi-cel in patients with chemorefractory aggressive non-Hodgkin lymphoma. Kite is an industry leader in the emerging field of cell therapy, which uses a patient's own immune cells to fight cancer. Gilead Sciences has completed the acquisition of Kite Pharma and is proud to officially welcome Kite’s more than 700 talented employees to the Gilead organization – for further details on the acquisition, click here. Kite stockholders and other investors are urged to read the tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement, in each case as may be amended from time to time, because they will contain important information which should be read carefully before any decision is made with respect to the tender offer. Gilead has paid $11.9 billion to make Kite a wholly owned subsidiary. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California. Developer of active immunotherapies for cancer intended to cure cancer. Gilead Completes Acquisition of Kite Pharma Gilead Sciences has completed the acquisition of Kite Pharma and is proud to officially welcome Kite’s more than 700 talented employees to the Gilead organization – for further details on the acquisition, click here. "CAR T has the potential to become one of the most powerful anti-cancer agents for hematologic cancers. Kite received priority review on May 29, 2017 with the Prescription Drug User Fee Act action date set for November 29, 2017. Through that acquisition, Gilead gained hepatitis C therapies that are among the world’s top-selling drugs. Now Gilead is betting that Kite can provide a similar payoff. Approval in Europe is expected in 2018. Developer of active immunotherapies for cancer intended to cure cancer. Gilead plans to finance the transaction with a combination of cash on hand, bank debt and senior unsecured notes. Gilead Sciences just announced a huge, major acquisition in the CAR-T space - that of Kite Pharma. The acquisition of Kite Pharma by Gilead Sciences, originally announced in August 2017, was completed this month. A talent acquisition (TA) partner will review your application based on the position requirements (education, work experience and overall background) and your submitted profile. Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. See Our Mission. “Congress should require the NIH to enforce the Bayh-Dole obligation to make the Kite Pharma Chimeric Antigen Receptors Technologies (CAR T) treatments available to the public on reasonable terms. Kite has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. Biotech giant Gilead Sciences, Inc. (GILD) announced that it will buy Kite Pharma, Inc. (KITE) to foray into the emerging field of cell therapy. Gilead Completes Acquisition of Kite Pharma. Our science. KEI notes that Kite reported spending $317 million in R&D from 2012 to June 30, 2017, and is … To access the webcast live via the internet, please connect to the company's website at www.gilead.com/investors 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Transactions are recorded by the highest transaction dollar value (rather than using the inflation adjusted values). The … With Acquisition of Kite Pharma, Gilead Becomes a 'Major Player' in CAR-T Arena. Kite Pharma, then trading at about $55, was among them. To access the phone replay, please call 1-855-859-2056 (U.S.) or 1-404-537-3406 (international) and dial the conference ID 77187238. The Offer to Purchase, the related Letter of Transmittal and certain other offer documents, as well as the Solicitation/Recommendation Statement, will be sent to all stockholders of Kite at no expense to them. This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, related to Gilead, Kite and the acquisition of Kite by Gilead that are subject to risks, uncertainties and other factors. Zacks Rank Gilead currently carries a Zacks Rank #2 (Buy). Jefferies LLC and Cowen and Company, LLC also provided advice to Kite. In a bid to diversify its portfolio and boost growth, Gilead Sciences has agreed to acquire Kite Pharma, a Santa Monica, Calif.-based immunotherapy specialist, for $11.9 billion. Gilead Sciences has completed the acquisition of Kite Pharma and is proud to officially welcome Kite’s more than 700 talented employees to the Gilead organization – for further details on the acquisition, click here. This year it has continued to Forty-Seven for $4.9 billion, Immunomedics for $21 billion, and … A replay of the webcast will be archived on the company's website for one year, and a phone replay will be available approximately two hours following the call through August 30, 2017. The transaction, which values Kite at approximately $11.9 billion, was unanimously approved by both the Gilead and Kite Boards of Directors and is anticipated to close in the fourth quarter of 2017. There's still money in the bank. To say the Read More. The Company’s most targeted sectors include life science (100%).. Join Mergr and gain access to Kite Pharma’s M&A summary, the M&A … Gilead has paid $11.9 billion to make Kite a wholly owned subsidiary. Sanofi Inks $359M Pharma Acquisition Deal to Boost Cell Therapy; Bristol Myers Squibb Gets FDA Priority Review for T-Cell Therapy; Key Strategies for Advancing Gene and Cell Therapy Development Kite is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. Centerview Partners is acting as exclusive financial advisor to Kite.